Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Kleiner Perkins breaks its rules with Corixa

Kleiner Perkins breaks its rules with Corixa

Immunex Corp. co-founder Steven Gillis is turning his immunology skills to vaccine development. Gillis has joined Corixa Corp., a Seattle-based Kleiner Perkins Caufield & Byers startup that today was to announce the completion of a first venture round of $15 million.

Other investors are Enterprise Partners, Interwest Partners, Olympic Venture Partners and Forward Ventures.

Corixa is the only biopharmaceutical startup funded by Kleiner Perkins in 1994

Read the full 738 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE